ATENOLOL TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

ATENOLOL

Предлага се от:

IVAX PHARMACEUTICALS INCORPORATED

АТС код:

C07AB03

INN (Международно Name):

ATENOLOL

дозиране:

50MG

Лекарствена форма:

TABLET

Композиция:

ATENOLOL 50MG

Начин на приложение:

ORAL

Броя в опаковка:

100

Вид предписание :

Prescription

Терапевтична област:

BETA-ADRENERGIC BLOCKING AGENTS

Каталог на резюме:

Active ingredient group (AIG) number: 0113847002; AHFS:

Статус Оторизация:

CANCELLED PRE MARKET

Дата Оторизация:

2018-07-24

Данни за продукта

_1_
PRODUCT MONOGRAPH
_Pr _
ATENOLOL TABLETS
Atenolol Tablets
50 mg and 100 mg
USP
Beta Adrenergic-receptor Blocking Agent
IVAX Pharmaceuticals, Inc.
140 Legrand Avenue
Northvale, New Jersey 07647
Control #: 099059
Canadian Distributor:
IVAX Pharmaceuticals Canada Inc.
1 Place Ville-Marie
Suite 3900
Montreal, Quebec
H3B 4M7
Date of Revision:
November 02, 2005
_2_
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION . . . . . . . . . . . . . . .
. . . . . . . . . . . . . 3
SUMMARY PRODUCT INFORMATION . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . 3
INDICATIONS AND CLINICAL USE . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . 3
CONTRAINDICATIONS . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . 4
WARNINGS AND PRECAUTIONS . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . 4
ADVERSE REACTIONS . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . 9
DRUG INTERACTIONS . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . 12
DOSAGE AND ADMINISTRATION . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . 13
OVERDOSAGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . 14
ACTION AND CLINICAL PHARMACOLOGY . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . 16
STORAGE AND STABILITY . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . 17
SPECIAL HANDLING INSTRUCTIONS . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . 17
DOSAGE FORMS, COMPOSITION AND PACKAGING . . . . . . . . . . . . . . .
. . . . . . . 18
PART II: SCIENTIFIC INFORMATION . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . 19
PHARMACEUTICAL INFORMATION . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . 19
CLINICAL TRIALS . . . . . . . . . . . . . . . . . . . . .